Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound

US11957044B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11957044-B2
Application numberUS-201816120916-A
CountryUS
Kind codeB2
Filing dateSep 4, 2018
Priority dateSep 5, 2017
Publication dateApr 9, 2024
Grant dateApr 9, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An organometallic compound represented by Formula 1:wherein, in Formula 1, groups and variables are the same as described in the specification.

First claim

Opening claim text (preview).

What is claimed is: 1. An organometallic compound represented by Formula 1: wherein, M in Formula 1 is a transition metal, X 1 in Formula 1 is nitrogen (N), X 2 to X 4 in Formula 1 are each independently carbon (C) or N, in Formula 1, a bond between X 1 and M is a coordinate bond, and one bond selected from a bond between X 2 and M, a bond between X 3 and M, and a bond between X 4 and M is a coordinate bond while the remaining two bonds are each independently be a covalent bond, n in Formula 1 is 0 or 1, wherein, when n is 0, CY 1 and CY 4 are not linked each other, CY 1 and CY 4 are identical to each other, in Formula 1, i) when n is 0, CY 1 is a group represented by one selected from Formulae A1-1 to A1-6; and ii) when n is 1, CY 1 is a group represented by one selected from Formulae A11-1 to A11-4, in Formulae A1-1 to A1-6 and A11-1 to A11-4, i) X 11 is *—N[(L 11 ) c11 -(R 11 )]—*′, *—B(R 11 )—*′, *—P(R 11 )—*′, *—C(R 11a )(R 11b )—*′, *—Si(R 11a )(R 11b )—*′, *—Ge(R 11a )(R 11b )—*′, *—S—*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O) 2 —*′, or *—C(═S)—*′, X 12 is C(R 12 ) or N, X 13 is C(R 13 ) or N, X 14 is C(R 14 ) or N, and X 15 is C(R 15 ) or N; ii) when X 14 is C(R 14 ) and X 15 is C(R 15 ), R 14 and R 15 are not linked each other; and iii) R 11a and R 11b , are optionally linked each other via a second linking group to form a substituted or unsubstituted C 5 -C 30 carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, in Formulae A1-1 to A1-6 and A1l-1 to A11-4, * may indicate a binding site to M in Formula 1, *′ may indicate a binding site to T 1 in Formula 1, and *” may indicate a binding site to T 4 in Formula 1, in Formula 1, CY 2 to CY 4 are each independently selected from a C 5 -C 30 carbocyclic group and a C 1 -C 30 heterocyclic group, in Formula 1, T 1 to T 4 are each independently selected from a single bond, a double bond, *—N[(L 5 ) c5 -(R 5 )]—*′, *—B(R 5 )—*′, *—P(R 5 )—*′, *—C(R 5 )(R 6 )—*′, *—Si(R 5 )(R 6 )—*′, *—Ge(R 5 )(R 6 )—*′, *—S—*′, *—Se—*′, *—O—*, *—C(═O)—*′, *—S(═O)—*′, *—S(═O) 2 —*′, *—C(R 5 )═*′, *═C(R 5 )—*′,*—C(R 5 )═C(R 6 )—*′, *—C(═S)—*′, and *—C≡C—*′, wherein R 5 and R 6 are optionally be linked each other via a first linking group to form a substituted or unsubstituted C 5 -C 30 carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, L 5 and L 11 are each independently selected from a single bond, a substituted or unsubstituted C 5 -C 30 carbocyclic group, and a substituted or unsubstituted C 1 -C 30 heterocyclic group, c5 and c11 are each independently an integer from 1 to 3, wherein, when c5 is two or more, two or more of groups L 5 are identical to or different from each other, and when c 11 is two or more, two or more of groups L 11 are identical to or different from each other, R 2 to R 6 , R 11 to R 15 , R 11a , and R 11b are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, —SF 5 , a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C 1 -C 60 alkyl group, a substituted or unsubstituted C 2 -C 60 alkenyl group, a substituted or unsubstituted C 2 -C 60 alkynyl group, a substituted or unsubstituted C 1 -C 60 alkoxy group, a substituted or unsubstituted C 3 -C 10 cycloalkyl group, a substituted or unsubstituted C 1 -C 10 heterocycloalkyl group, a substituted or unsubstituted C 3 -C 10 cycloalkenyl group, a substituted or unsubstituted C 1 -C 10 heterocycloalkenyl group, a substituted or unsubstituted C 6 -C 60 aryl group, a substituted or unsubstituted C 7 -C 60 alkyl aryl group, a substituted or unsubstituted C 6 -C 60 aryloxy group, a substituted or unsubstituted C 6 -C 60 arylthio group, a substituted or unsubstituted C 7 -C 60 arylalkyl group, a substituted or unsubstituted C 1 -C 60 heteroaryl group, a substituted or unsubstituted C 2 -C 60 alkyl heteroaryl group, a substituted or unsubstituted C 1 -C 60 heteroaryloxy group, a substituted or unsubstituted C 1 -C 60 heteroarylthio group, a substituted or unsubstituted C 2 -C 60 heteroaryl alkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or un substituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q 1 )(Q 2 ), —Si(Q 3 )(Q 4 )(Q 5 ), —B(Q 6 )(Q 7 ), and —P(═O)(Q 8 )(Q 9 ), provided that when CY 1 is a group represented by Formula A1-1, then i) X 11 is O and at least one of X 12 to X 15 is N, or ii) X 11 is *—S—*′ or *—Se—*′, a2 to a4 are each independently an integer from 0 to 20, in Formula 1, two or more selected from groups R 2 in the number of a2 are optionally linked each other to forma substituted or unsubstituted C 5 -C 30 carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, in Formula 1, two or more selected from groups R 3 in the number of a3 are optionally linked each other to form a substituted or unsubstituted C 5 -C 30 carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, in Formula 1, two or more selected from groups R 4 in the number of a4 are optionally linked each other to form a substituted or unsubstituted C 5 -C 30 carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, in Formula 1, two or more of R 2 to R 4 are optionally linked each other to form a substituted or unsubstituted C 5 -C 30 carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, in Formula 1, one of R 5 and R 6 and one of R 2 to R 4 are optionally linked each other to form a substituted or unsubstituted C 5 -C 30 carbocyclic group or a substituted or unsubstituted C 1 -C 30 heterocyclic group, at least one substituent of the substituted C 5 -C 30 carbocyclic group, the substituted C 1 -C 30 heterocyclic group, the substituted C 1 -C 60 alkyl group, the substituted C 2 -C 60 alkenyl group, the substituted C 2 -C 60 alkynyl group, the substituted C 1 -C 60 alkoxy group, the substituted C 3 -C 10 cycloalkyl group, the substituted C 1 -C 10 heterocycloalkyl group, the substituted C 3 -C 10 cycloalkenyl group, the substituted C 1 -C 10 heterocycloalkenyl group, the substituted C 6 -C 60 aryl group, the substituted C 7 -C 60 alkyl aryl group, the substituted C 6 -C 60 aryloxy group, the substituted C 6 -C 60 arylthio group, the substituted C 7 -C 60 aryl alkyl group, the substituted C 1 -C 60 heteroaryl group, the substituted C 2 -C 60 alkyl heteroaryl group, the substituted C 1 -C 60 heteroaryloxy group, the substituted C 1 -C 60 heteroarylthio group, the C 2 -C 60 heteroaryl alkyl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group is selected from: deuterium, —F, —Cl, —Br, —I, —CD 3 , —CD 2 H, —CDH 2 , —CF 3 , —CF 2 H, —CFH 2 , a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, and a C 1 -C 60 alkoxy group; a C 1 -C 60 alkyl group, a C 2 -C 60 alkenyl group, a C 2 -C 60 alkynyl group, an

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11957044B2 cover?
An organometallic compound represented by Formula 1:wherein, in Formula 1, groups and variables are the same as described in the specification.
Who is the assignee on this patent?
Samsung Electronics Co Ltd
What technology area does this patent fall under?
Primary CPC classification H10K85/346. Mapped technology areas include Electricity.
When was this patent published?
Publication date Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).